TY - JOUR
T1 - Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries
AU - Fudim, Marat
AU - Zhong, Lin
AU - Patel, Kershaw V.
AU - Khera, Rohan
AU - Abdelmalek, Manal F.
AU - Diehl, Anna Mae
AU - McGarrah, Robert W.
AU - Molinger, Jeroen
AU - Moylan, Cynthia A.
AU - Rao, Vishal N.
AU - Wegermann, Kara
AU - Neeland, Ian J.
AU - Halm, Ethan A.
AU - Das, Sandeep R.
AU - Pandey, Ambarish
N1 - Funding Information:
Dr Fudim is supported by a Mario Family Award and Translating Duke Health Award; and consulting fees from AstraZeneca, AxonTherapies, CVRx, Daxor, Edwards LifeSciences, Galvani, NXT Biomedical, and Respicardia. Dr Pandey reported serving on the advisory board of Roche Diagnostics and received non-financial support from Pfizer and Merck. Dr Neeland reports being a former speaker/consultant for Boehringer Ingelheim, being a former scientific advisory board member for AMRA Medical, receiving a grant from Novo Nordisk, and receiving prior consulting honoraria from Merck. The remaining authors have no disclosures to report.
Funding Information:
Dr Fudim was supported by K23HL151744 from the National Heart, Lung, and Blood Institute (NHLBI) and the American Heart Association grant 20IPA35310955. Dr Khera was supported by grant 5T32HL125247-02 from the NHLBI and grant UL1TR001105 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). Dr Rao reports grants from NIH (T32 HL069749). Dr Pandey has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging GEMSSTAR Grant (1R03AG067960), and Applied Therapeutics.
Publisher Copyright:
© 2021 The Authors.
PY - 2021/11/16
Y1 - 2021/11/16
N2 - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are increasing in prevalence. The independent association between NAFLD and downstream risk of HF and HF subtypes (HF with preserved ejection fraction and HF with reduced ejection fraction) is not well established. METHODS AND RESULTS: This was a retrospective, cohort study among Medicare beneficiaries. We selected Medicare beneficiaries without known prior diagnosis of HF. NAFLD was defined using presence of 1 inpatient or 2 outpatient claims using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), claims codes. Incident HF was defined using at least 1 inpatient or at least 2 outpatient HF claims during the follow-up period (October 2015– December 2016). Among 870 535 Medicare patients, 3.2% (N=27 919) had a clinical diagnosis of NAFLD. Patients with NAFLD were more commonly women, were less commonly Black patients, and had a higher burden of comorbidities, such as diabetes, obesity, and kidney disease. Over a mean 14.3 months of follow-up, patients with (versus without) baseline NAFLD had a significantly higher risk of new-onset HF in unadjusted (6.4% versus 5.0%; P<0.001) and adjusted (adjusted hazard ratio [HR] [95% CI], 1.23 [1.18–1.29]) analyses. Among HF subtypes, the association of NAFLD with downstream risk of HF was stronger for HF with preserved ejection fraction (adjusted HR [95% CI], 1.24 [1.14–1.34]) compared with HF with reduced ejection fraction (adjusted HR [95% CI], 1.09 [0.98–1.2]). CONCLUSIONS: Patients with NAFLD are at an increased risk of incident HF, with a higher risk of developing HF with preserved ejection fraction versus HF with reduced ejection fraction. The persistence of an increased risk after adjustment for clinical and demographic factors suggests an epidemiological link between NAFLD and HF beyond the basis of shared risk factors that requires further investigation.
AB - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are increasing in prevalence. The independent association between NAFLD and downstream risk of HF and HF subtypes (HF with preserved ejection fraction and HF with reduced ejection fraction) is not well established. METHODS AND RESULTS: This was a retrospective, cohort study among Medicare beneficiaries. We selected Medicare beneficiaries without known prior diagnosis of HF. NAFLD was defined using presence of 1 inpatient or 2 outpatient claims using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), claims codes. Incident HF was defined using at least 1 inpatient or at least 2 outpatient HF claims during the follow-up period (October 2015– December 2016). Among 870 535 Medicare patients, 3.2% (N=27 919) had a clinical diagnosis of NAFLD. Patients with NAFLD were more commonly women, were less commonly Black patients, and had a higher burden of comorbidities, such as diabetes, obesity, and kidney disease. Over a mean 14.3 months of follow-up, patients with (versus without) baseline NAFLD had a significantly higher risk of new-onset HF in unadjusted (6.4% versus 5.0%; P<0.001) and adjusted (adjusted hazard ratio [HR] [95% CI], 1.23 [1.18–1.29]) analyses. Among HF subtypes, the association of NAFLD with downstream risk of HF was stronger for HF with preserved ejection fraction (adjusted HR [95% CI], 1.24 [1.14–1.34]) compared with HF with reduced ejection fraction (adjusted HR [95% CI], 1.09 [0.98–1.2]). CONCLUSIONS: Patients with NAFLD are at an increased risk of incident HF, with a higher risk of developing HF with preserved ejection fraction versus HF with reduced ejection fraction. The persistence of an increased risk after adjustment for clinical and demographic factors suggests an epidemiological link between NAFLD and HF beyond the basis of shared risk factors that requires further investigation.
KW - Heart failure
KW - Heart failure with preserved ejection fraction
KW - Heart failure with reduced ejection fraction
KW - Nonalcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85121958289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121958289&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.021654
DO - 10.1161/JAHA.121.021654
M3 - Article
C2 - 34755544
AN - SCOPUS:85121958289
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 22
M1 - e021654
ER -